文献速递眼底病与葡萄膜炎

利用治疗退出时的OCT血管成像评估新生血管性年龄相关性黄斑变性的复发风险

Evaluating the risk of recurrence in neovascular age-related macular degeneration using OCT-angiography at the time of treatment exit.
PubMed 文献 · Br J Ophthalmol · 2026-03-20

回顾性观察研究纳入抗VEGF治疗达到预设退出标准的新生血管性年龄相关性黄斑变性稳定期患者,用OCT血管成像量化黄斑新生血管病灶面积、血管密度、分形维数和滋养血管高度。复发组血管密度显著高于未复发组(0.60±0.15 vs 0.47±0.11,p=0.015),OCT-A有助于计算停药后复发风险。

要点

  • 77/281只眼(27.4%)达到退出标准,34只眼有可靠OCT-A资料进入分析。
  • 复发组血管密度0.60±0.15,显著高于未复发组0.47±0.11(p=0.015)。
  • 1型MNV和低滋养血管对复发有保护性趋势,但未达统计学显著。

核心结论

  • OCT-A有助于计算即将停止抗VEGF治疗的新生血管性年龄相关性黄斑变性患者的复发风险。
  • 血管密度高的患者即使病情稳定,也可能需要更密切的随访或继续抗VEGF治疗。

研究设计与样本

  • 回顾性观察性研究。
  • 纳入接受treat-and-extend方案治疗并达到预设退出标准的稳定、非活动性新生血管性年龄相关性黄斑变性患者。
  • 819只眼诊断为新生血管性年龄相关性黄斑变性,281只眼有2年随访,77只眼(27.4%)达到退出标准。
  • 34只眼(33例患者,其中15例女性)具有可靠OCT-A资料被进一步分析,平均年龄80.35(±9.29)岁,注射次数16.68(±8.22),退出前治疗时长36.15(±16.63)个月。

主要发现

  • 退出后23只眼保持非活动,随访23.00(±16.18)个月;11只眼在13.36(±9.90)个月后复发。
  • 复发组血管密度0.60(±0.15)vs 未复发组0.47(±0.11),p=0.015,复发组显著高于未复发组。
  • 1型黄斑新生血管和低滋养血管表现出保护性趋势,但未达统计学显著。

关键数值与推荐

  • 退出标准为预先设定,原文未列出具体条款。
  • OCT-A量化指标包括病灶面积、血管密度、分形维数和滋养血管高度。

临床怎么用

  • 作者认为OCT-A可用于计算即将停止抗VEGF治疗患者的复发风险。
  • 作者认为血管密度高的患者即使病情稳定,也可能需要更密切的随访或继续抗VEGF治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND/AIMS: To find biomarkers on OCT-angiography (OCT-A) that indicate a higher risk of recurrence in neovascular age-related macular degeneration (nAMD) patients before anti-vascular endothelial growth factor (anti-VEGF) therapy termination. METHODS: Retrospective, observational study. Stable, inactive nAMD patients who had been treated with a treat-and-extend regimen and met the predefined exit criteria were included. The macular neovascularisation (MNV) lesion was imaged on OCT-A. Lesion area, vessel density (VD), fractal dimension and height of feeder vessel were quantified. Patients with disease recurrence after termination were compared with those who stayed inactive. RESULTS: Out of 819 eyes diagnosed with nAMD and 281 with a 2-year follow-up, 77 (27.4%) reached the exit criteria. Thirty-four eyes of 33 (15 female) patients with reliable OCT-A were further analysed. Mean age was 80.35 (±9.29) years, the number of injections was 16.68 (±8.22). Treatment duration before exit was 36.15 (±16.63) months. After exit, 23 eyes stayed inactive for a follow-up period of 23.00 (±16.18) months, and 11 experienced recurrence after 13.36 (±9.90) months. VD was significantly higher in the recurrent versus inactive group with 0.60 (±0.15) versus 0.47 (±0.11), p=0.015. There was an insignificant tendency for the protective properties of type 1 MNV and a low feeder vessel. CONCLUSION: OCT-A is useful in the risk calculation for recurrence in patients who are about to discontinue anti-VEGF treatments in nAMD. Patients with a high VD might need closer follow-ups or continued anti-VEGF treatments even if inactive.

来源:Br J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Jaggi D, Marugg S, Berger LE, et al. Evaluating the risk of recurrence in neovascular age-related macular degeneration using OCT-angiography at the time of treatment exit. Br J Ophthalmol. 2026. PMID: 41072938. doi:10.1136/bjo-2025-327721

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。